Uneingeschränkter Zugang

Characterisation of a new molecule based on two E2 sequences from bovine viral diarrhoea-mucosal disease virus fused to the human immunoglobulin Fc fragment

Alaín González Pose
Alaín González Pose
, 
Raquel Montesino Seguí
Raquel Montesino Seguí
, 
Rafael Maura Pérez
Rafael Maura Pérez
, 
Florence Hugues Salazar
Florence Hugues Salazar
, 
Ignacio Cabezas Ávila
Ignacio Cabezas Ávila
, 
Claudia Altamirano Gómez
Claudia Altamirano Gómez
, 
Oliberto Sánchez Ramos
Oliberto Sánchez Ramos
 und 
Jorge Roberto Toledo
Jorge Roberto Toledo
   | 26. Jan. 2021
Journal of Veterinary Research's Cover Image
Über diesen Artikel
Vorheriger Artikel
Nächster Artikel
Zitieren
Online veröffentlicht: 26. Jan. 2021
Seitenbereich: 27 - 37
Eingereicht: 15. Juli 2020
Akzeptiert: 29. Dez. 2020
DOI: https://doi.org/10.2478/jvetres-2021-0006
Schlüsselwörter
© 2021 A.G. Pose et al. published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Fig 1

Expression of the bvde2fc gene and assembly of the recombinant adenoviral vector carrying the gene (AdBVDE2Fc)A – Scheme of the transcriptional unit for bvde2fc gene expression. pCMV – early/immediate cytomegalovirus promoter; S – spacer of glycine and serine; H – histidine tag; hFc – Fc segment of human immunoglobulin; bGH poly (A) – sequence of the transcriptional termination from the bovine growth hormone B – Expression assay of the bvde2fc gene by transfecting the pcDNA 3.1- bvde2fc plasmid into HEK-293 cells. MWM – molecular weight marker; 1 – supernatant of HEK-293 cells transduced without plasmid; 2 – supernatant of HEK-293 cells transduced with the pcDNA 3.1- bvde2fc plasmid; WB – Western blot C – Fluorescent halo indicating the correct assembly of AdBVDE2Fc
Expression of the bvde2fc gene and assembly of the recombinant adenoviral vector carrying the gene (AdBVDE2Fc)A – Scheme of the transcriptional unit for bvde2fc gene expression. pCMV – early/immediate cytomegalovirus promoter; S – spacer of glycine and serine; H – histidine tag; hFc – Fc segment of human immunoglobulin; bGH poly (A) – sequence of the transcriptional termination from the bovine growth hormone B – Expression assay of the bvde2fc gene by transfecting the pcDNA 3.1- bvde2fc plasmid into HEK-293 cells. MWM – molecular weight marker; 1 – supernatant of HEK-293 cells transduced without plasmid; 2 – supernatant of HEK-293 cells transduced with the pcDNA 3.1- bvde2fc plasmid; WB – Western blot C – Fluorescent halo indicating the correct assembly of AdBVDE2Fc

Fig 2

Expression of the bvde2fc gene by transducing mammalian cell lines from different species with AdBVDE2Fc. 1 – supernatant of non-transduced cells; 2 – supernatant of transduced cells with AdBVDE2Fc at MOI 100
Expression of the bvde2fc gene by transducing mammalian cell lines from different species with AdBVDE2Fc. 1 – supernatant of non-transduced cells; 2 – supernatant of transduced cells with AdBVDE2Fc at MOI 100

Fig 3

Purification of BVDE2Fc by IMACA – Analysis by SDS-PAGE and Western blot of different steps of the purification process. 1 – initial sample; 2 – unbound material; 3 – wash at 20 mM imidazole; 4 – elution at 80 mM imidazole B – Analysis by SDS-PAGE and Western blot of the purified BVDE2Fc. 1 – in reduced conditions; 2 – in non-reduced conditions C – HPLC size exclusion chromatography of the purified BVDE2Fc. Upper graph – external standard. 1 – 660 kDa; 2 – 440 kDa; 3 – 158 kDa; 4 – 75 kDa; 5 – 43 kDa; 6 – 13.7 kDa. Lower graph – BVDE2Fc. T – tetramers; D – dimers; M – monomers
Purification of BVDE2Fc by IMACA – Analysis by SDS-PAGE and Western blot of different steps of the purification process. 1 – initial sample; 2 – unbound material; 3 – wash at 20 mM imidazole; 4 – elution at 80 mM imidazole B – Analysis by SDS-PAGE and Western blot of the purified BVDE2Fc. 1 – in reduced conditions; 2 – in non-reduced conditions C – HPLC size exclusion chromatography of the purified BVDE2Fc. Upper graph – external standard. 1 – 660 kDa; 2 – 440 kDa; 3 – 158 kDa; 4 – 75 kDa; 5 – 43 kDa; 6 – 13.7 kDa. Lower graph – BVDE2Fc. T – tetramers; D – dimers; M – monomers

Fig 4

Analysis of the N-glycan profile released after BVDE2Fc deglycosylationA – N-glycan analysis by a NP-HPLC-Amide 80 column. The N-glycan retention times were expressed as glucose units (GU) by comparison with a standard 2AB-labeled dextran hydrolysate B – N-glycan analysis by HPLC-weak anion exchange chromatography. Blue – N-glycans of IgG as external standard; Red – N-glycans of BVDE2Fc; RT – retention time Inset – SDS-PAGE of BVDE2Fc. 1 – glycosylated with PNGase-F; 2 – deglycosylated with PNGase-F
Analysis of the N-glycan profile released after BVDE2Fc deglycosylationA – N-glycan analysis by a NP-HPLC-Amide 80 column. The N-glycan retention times were expressed as glucose units (GU) by comparison with a standard 2AB-labeled dextran hydrolysate B – N-glycan analysis by HPLC-weak anion exchange chromatography. Blue – N-glycans of IgG as external standard; Red – N-glycans of BVDE2Fc; RT – retention time Inset – SDS-PAGE of BVDE2Fc. 1 – glycosylated with PNGase-F; 2 – deglycosylated with PNGase-F

Fig 5

Characterisation of BVDE2Fc as immunogenA – Humoral immune response after inoculating mice with 20 μg of BVDE2Fc B – Analysis of mice sera by coating with deglycosylated BVDE2Fc in ELISA assays C – Analysis of mice sera by coating with EPOFc in ELISA assays. NC – negative control; NC t:42 – negative control of the pool from mice sera at 42 days. The arrow indicates the second inoculation. Bars represent the standard deviation. OD values were compared by the Kruskal–Wallis test and the Dunn post-test (A, B), and by the Mann–Whitney test (C). * P < 0.05; ** P < 0.01; *** P < 0.001
Characterisation of BVDE2Fc as immunogenA – Humoral immune response after inoculating mice with 20 μg of BVDE2Fc B – Analysis of mice sera by coating with deglycosylated BVDE2Fc in ELISA assays C – Analysis of mice sera by coating with EPOFc in ELISA assays. NC – negative control; NC t:42 – negative control of the pool from mice sera at 42 days. The arrow indicates the second inoculation. Bars represent the standard deviation. OD values were compared by the Kruskal–Wallis test and the Dunn post-test (A, B), and by the Mann–Whitney test (C). * P < 0.05; ** P < 0.01; *** P < 0.001

Fig 6

Evaluation of sera from bovines positive to different BVD-MDV subtypes by coating with BVDE2Fc in ELISA assays. Bars represent the standard deviation. OD values were compared by the Kruskal–Wallis test and the Dunn post-test (A, B), and by the Mann–Whitney test (C). * – P < 0.05; ** – P < 0.01; *** – P < 0.001; AI – animal identification; VS – viral subtype; NC – negative control; ND – not determined; black line – cut-off value
Evaluation of sera from bovines positive to different BVD-MDV subtypes by coating with BVDE2Fc in ELISA assays. Bars represent the standard deviation. OD values were compared by the Kruskal–Wallis test and the Dunn post-test (A, B), and by the Mann–Whitney test (C). * – P < 0.05; ** – P < 0.01; *** – P < 0.001; AI – animal identification; VS – viral subtype; NC – negative control; ND – not determined; black line – cut-off value

Prediction of N-glycan structures using the Glycostore glycobase
eISSN:
2450-8608
Sprache:
Englisch
Zeitrahmen der Veröffentlichung:
4 Hefte pro Jahr
Fachgebiete der Zeitschrift:
Biologie, Molekularbiologie, Mikrobiologie und Virologie, andere, Medizin, Veterinärmedizin
Zeitschrift RSS Feed